Ann: Application for quotation of securities - PAA, page-55

Thanks @Bunter62,
The unknown of course is weather or not its a BP who may be interested or multiple BPs. There have been multiple failed clinical trials, I found 10 without any effort, [see below] 3 of them big Pharma so the interest is there. On this basis I think it fair to assume we should have multiple interested parties.

The other thing is, we have discussed the benefit on this forum of having a ODD and without a doubt it is a big deal. But the FDA advising accelerated approval is a possibility has possibly slipped under the radar. If approved after the Adaptive 2/3 trial, it means MPL could be on the market 12 months earlier. And unbelievably it could be a billion dollar drug in that first full year or shortly after.

The fact that these companies have already conducted trials also tells us a lot of their market research has already been done.

My Target is A$ 2-3 per share but that is just what will make very very very comfortable and not based on anything of substance.



1. Ceftriaxone in ALS Study (CAALS) - No specific company sponsor
2. NP001 Phase 2 trial - Neuraltus Pharmaceuticals
3. Mexiletine Phase 3 trial - Biohaven Pharmaceuticals
4. Olesoxime in ALS Phase 3 trial - Roche
5. NP001 Phase 3 trial - Neuraltus Pharmaceuticals
6. Arimoclomol in ALS Phase 2/3 trial - CytRx Corporation
7. Biogen's dexpramipexole Phase 3 trial - Biogen
8. Brainstorm Cell Therapeutics Phase 3 trial of NurOwn - BrainStorm Cell Therapeutics
9. Gilenya (fingolimod) Phase 2 trial in ALS - Novartis
10. Tirasemtiv Phase 2b trial - Cytokinetics


Cheers